Singin' the CRO Blues
Executive Summary
The big three CROs--Quintiles, Parexel, & Covance have suffered contract cancellations, less-than-glowing earnings reports, and diving stock prices over the last 12 months. But, while the near-term continues to look fairly bleak, there's cause for hope on the horizon. CROs are increasingly seen as strategic partners, rather than as a means of handling overflow. And there's likely to be major opportunities for companies offering specialized services. One particularly promising area involves using the Internet to streamline R&D--for example, web-enabled clinical trials.
You may also be interested in...
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.